Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
23 Avril 2024 - 1:30PM
Business Wire
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing
novel immunological agents to treat various cancers, today
announced the Company will release its first quarter 2024 financial
results before the market opens on Tuesday, May 7, 2024. Agenus
executives will host a conference call and webcast at 8:30 a.m. ET
that morning to discuss the results and provide a corporate
update.
Conference Call:
To access dial-in numbers, please register here.
Conference ID: 73242
A live webcast and replay of the conference call will be
accessible on the company’s website at
https://investor.agenusbio.com/events-and-presentations and via
https://events.q4inc.com/attendee/928123199.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward-Looking
Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding a its botensilimab
and balstilimab programs, expected regulatory timelines and
filings, and any other statements containing the words "may,"
"believes," "expects," "anticipates," "hopes," "intends," "plans,"
"forecasts," "estimates," "will," “establish,” “potential,”
“superiority,” “best in class,” and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Annual Report on
Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240423870121/en/
Investors 917-362-1370
investor@agenusbio.com Media
917-362-1370 communications@agenusbio.com
Agenus (NASDAQ:AGEN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Agenus (NASDAQ:AGEN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024